James K. Luce

2.6k total citations
33 papers, 2.0k citations indexed

About

James K. Luce is a scholar working on Oncology, Pathology and Forensic Medicine and Dermatology. According to data from OpenAlex, James K. Luce has authored 33 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 8 papers in Pathology and Forensic Medicine and 7 papers in Dermatology. Recurrent topics in James K. Luce's work include Cancer Treatment and Pharmacology (9 papers), Chemotherapy-related skin toxicity (6 papers) and Lymphoma Diagnosis and Treatment (5 papers). James K. Luce is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Chemotherapy-related skin toxicity (6 papers) and Lymphoma Diagnosis and Treatment (5 papers). James K. Luce collaborates with scholars based in United States, Canada and Germany. James K. Luce's co-authors include Emil Frei, Jeffrey A. Gottlieb, Robert W. Talley, Laurence H. Baker, Edward L. Middleman, Gianni Bonadonna, Robert M. OʼBryan, John P. Whitecar, Ti Li Loo and Edwin M. Jacobs and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Cancer.

In The Last Decade

James K. Luce

33 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James K. Luce United States	23	1.1k	560	485	342	338	33	2.0k
Robert W. Talley United States	23	1.1k 1.1×	722 1.3×	456 0.9×	695 2.0×	221 0.7×	53	2.4k
C B Pratt United States	29	975 0.9×	842 1.5×	712 1.5×	476 1.4×	185 0.5×	65	2.6k
Johannes Blom Sweden	25	1.3k 1.2×	739 1.3×	278 0.6×	435 1.3×	169 0.5×	87	2.4k
Ronald L. Stephens United States	24	1.3k 1.3×	648 1.2×	394 0.8×	813 2.4×	106 0.3×	83	2.6k
Tate Thigpen United States	26	1.2k 1.1×	601 1.1×	493 1.0×	389 1.1×	157 0.5×	49	2.9k
Jacob D. Bitran United States	32	1.5k 1.4×	1.1k 1.9×	462 1.0×	578 1.7×	97 0.3×	138	3.0k
Robert E. Wittes United States	21	922 0.9×	379 0.7×	618 1.3×	320 0.9×	70 0.2×	42	2.0k
J Wernz United States	20	1.6k 1.5×	182 0.3×	363 0.7×	840 2.5×	398 1.2×	28	2.3k
R. Erttmann Germany	27	858 0.8×	563 1.0×	631 1.3×	163 0.5×	243 0.7×	83	2.6k
Troy H. Guthrie United States	22	2.0k 1.9×	409 0.7×	908 1.9×	236 0.7×	243 0.7×	69	3.8k

Countries citing papers authored by James K. Luce

Since Specialization

Citations

This map shows the geographic impact of James K. Luce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James K. Luce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James K. Luce more than expected).

Fields of papers citing papers by James K. Luce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James K. Luce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James K. Luce. The network helps show where James K. Luce may publish in the future.

Co-authorship network of co-authors of James K. Luce

This figure shows the co-authorship network connecting the top 25 collaborators of James K. Luce. A scholar is included among the top collaborators of James K. Luce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James K. Luce. James K. Luce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Balaban, Edward P., Steve Perkins, Richard G. Sheehan, et al.. (1994). Double Modulation of 5-Fluorouracil in the Treatment of Advanced Colorectal Carcinoma: Report of a Trial with Sequential Methotrexate, Intravenous (Loading Dose) Folinic Acid, 5-Fluorouracil, and a Literature Review. Cancer Investigation. 12(1). 12–19. 2 indexed citations

Luce, James K., et al.. (1990). Extravasation of Doxorubicin from Vascular Access Devices. PubMed. 6(2). 103–107. 5 indexed citations

Luce, James K., et al.. (1990). Doxorubicin-associated flare reactions.. PubMed. 17(3). 387–9. 21 indexed citations

Luce, James K., et al.. (1989). Ocular Adverse Reactions Associated with Adriamycin (Doxorubicin). American Journal of Ophthalmology. 108(6). 709–711. 23 indexed citations

Luce, James K., et al.. (1989). Accidental acute exposure to doxorubicin. Cancer Nursing. 12(6). 329???331–329???331. 4 indexed citations

Luce, James K., et al.. (1988). Efficacy of mesna in preventing further cyclophosphamide‐lnduced hemorrhagic cystitis. Medical and Pediatric Oncology. 16(6). 372–374. 22 indexed citations

Chlebowski, Rowan T., et al.. (1986). Long-term survival following relapse after 5-FU but not CMF adjuvant breast cancer therapy. Breast Cancer Research and Treatment. 7(1). 23–30. 86 indexed citations

Rt, Chlebowski, et al.. (1981). Significance of relapse after adjuvant treatment with combination chemotherapy or 5-fluorouracil alone in high-risk breast cancer. A Western Cancer Study Group Project.. PubMed. 41(11 Pt 1). 4399–403. 29 indexed citations

McKelvey, Eugene M., James K. Luce, V. K. Vaitkevicius, et al.. (1977). Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma. Cancer. 39(1). 5–10. 28 indexed citations

10.

Haas, Charles D., Charles A. Coltman, Jeffrey A. Gottlieb, et al.. (1976). Phase II evaluation of bleomycin.A Southwest Oncology Group study. Cancer. 38(1). 8–12. 89 indexed citations

11.

Einhorn, Lawrence H., M. A. Burgess, Carlos Vallejos, et al.. (1974). Prognostic correlations and response to treatment in advanced metastatic malignant melanoma.. PubMed. 34(8). 1995–2004. 168 indexed citations

12.

Barranco, S. C., James K. Luce, Marvin M. Romsdahl, & Ronald M. Humphrey. (1973). Bleomycin as a possible synchronizing agent for human tumor cells in vivo.. PubMed. 33(4). 882–7. 64 indexed citations

13.

OʼBryan, Robert M., James K. Luce, Robert W. Talley, et al.. (1973). Phase II evaluation of adriamycin in human neoplasia. Cancer. 32(1). 1–8. 322 indexed citations

14.

Johnson, Douglas E., James J. Butler, & James K. Luce. (1972). Histiocytic Reticulum Cell Sarcoma Presenting as a Testicular Tumor. The Journal of Urology. 107(3). 425–428. 13 indexed citations

15.

Middleman, Edward L., James K. Luce, & Emil Frei. (1971). Clinical trials with adriamycin. Cancer. 28(4). 844–850. 186 indexed citations

16.

Luce, James K., Jess F. Gamble, Henry E. Wilson, et al.. (1971). Combined cyclophosphamide, vincristine, and prednisone therapy of malignant lymphoma. Cancer. 28(2). 306–317. 162 indexed citations

17.

Shirakawa, S, James K. Luce, Ian F. Tannock, & Emil Frei. (1970). Cell proliferation in human melanoma. Journal of Clinical Investigation. 49(6). 1188–1199. 80 indexed citations

18.

Loo, Ti Li, James K. Luce, John H. Jardine, & Emil Frei. (1968). Pharmacologic studies of the antitumor agent 5-(dimethyltriazeno)imidazole-4-carboxamide.. PubMed. 28(12). 2448–53. 41 indexed citations

19.

Luce, James K., Gerald P. Bodey, & Emil Frei. (1967). The Systemic Approach to Cancer Therapy. Hospital Practice. 2(10). 42–55. 9 indexed citations

20.

Ahearn, Michael J., Charles Lewis, Lee Ann Campbell, & James K. Luce. (1967). Nuclear Bleb Formation in Human Bone Marrow Cells during Cytosine Arabinoside Therapy. Nature. 215(5097). 196–197. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact